Human parvovirus B19 (B19V) causes myriads of clinical diseases; however, owing to lack of awareness and undetermined clinical impact, it has failed to become a virus pathogen of global concern. Cryptically, B19V causes significant morbidity and mortality. Half of the world population and 60 per cent of Indians are known to be serologically naive and are at risk of acquiring B19V infections. Cumulatively, our data showed 21.3 per cent B19V-infected patients with juvenile chronic arthropathy, recurrent abortions, multi-transfused thalassaemia and leukaemia. In addition, B19V-infected cases that ended fatally included patients with pure red cell aplasia, fulminant hepatitis and haemophagocytic syndrome. Novel clinical associations of B19V observed were amegakaryocytic thrombocytopaenia, myositis and non-occlusive ischaemic gangrene of bowel. B19V possesses multiple receptors which are distributed widely in human tissues. Vascular endothelial cell infection by B19V causes endothelialitis and vasculitic injuries besides antibody-dependent enhancement which empowered B19V to cause multiorgan diseases. Owing to lack of suitable animal model for B19V, true causal role remains to be determined, but numerous reports on B19V infections substantiate a causal role in multiorgan diseases. Hence, B19V infections need to be recognized, investigated and treated besides making efforts on vaccine developments.
Introduction
Human parvovirus B19 (B19V) infections are known to be associated with numerous clinical manifestations, which often culminate in sinister sequels; however, unfortunately, B19V infections remain greatly under-recognized and human sufferings continue incognito. B19V belongs to the genus Erythrovirus in the family Parvoviridae and is the smallest DNA virus (5.5 Kb) . Although discovered in 1975 1 , the clinical diseases caused by B19V were recognized much later (1981) (1982) (1983) (1984) (1985) (1986) (1987) beginning with transient aplastic crisis in patients with haemolytic anaemia, erythema infectiosum (fifth disease), arthropathy and non-immune hydrops foetalis [2] [3] [4] [5] . B19V is an obligate human pathogenic virus 6 , and its clinical spectrum has gradually increased over decades [7] [8] [9] [10] [11] [12] . Further, B19V has gained the status of an expanding 13 and an emerging virus 14 . Still, B19V infections could not gain much clinical importance Clinical impact & pathogenic mechanisms of human parvovirus B19: A multiorgan disease inflictor incognito Janak Kishore 1 & Divya Kishore 2 since most of B19V infections remain asymptomatic or self-limiting 6 . Thus, most clinical infections due to B19V go undiagnosed.
Transmission of B19V infection is largely through respiratory droplet, transfusion of B19V viraemic blood or blood components or transplacentally 6 . Droplet infection is the most common mode of transmission of B19V where it at first multiplies in the throat and then results in viraemia with very high titres of B19V 6, 7 . Laboratory diagnosis of acute B19V infections is usually made by detecting B19V-specific immunoglobulin G (IgM) antibodies in the serum by ELISA and/or B19V DNA in serum or bone marrow aspirate [6] [7] [8] 10 . In case of infected tissues, B19V can be detected by in situ hybridization but commonly by polymerase chain reaction (PCR) or real-time PCR which is more specific though costly and technically demanding. Other modalities are electron microscopy to demonstrate B19V virions in serum since acute B19V infections result in high titre viraemia (up to 10 12 /ml) 6 ; further, cytomorphology of bone marrow aspirate may show giant pronormoblast measuring 25-32 μm with large eosinophilic nuclear inclusion bodies, cytoplasmic vacuolization and dog ear projections called 'Lantern cells' 10 that provide presumptive diagnosis of B19V infection. There is no specific treatment of B19V infections; however, infusions of intravenous IgG (IVIG) 15 which contains sufficient B19V neutralizing antibodies help in clearance of virus, but being very costly is neither recommended by clinicians nor is affordable by patients in developing countries specially. Cumulative reasons culminated in slackness in considering B19V infections as a possible cause of illness in patients as well as in investigating and even if found in treating for B19V infections. Thus, an unaccounted percentage of patients silently suffers from B19V infections.
Approach to unveil clinical manifestations further
To unveil various clinical manifestations of B19V infection, suspected and even unknown but pathogenically rational cases were investigated. Children with juvenile chronic arthropathy (n=69) now known as juvenile idiopathic arthropathy, were studied and B19V infection was observed in 27 per cent children 16 . Next, B19V-induced clinical cases ending fatally with pure red cell aplasia (PRCA), severe anaemia and thrombocytopaenia with hepatitis in a child and haemophagocytic syndrome in an infant were reported [17] [18] [19] . Further three novel clinical associations of B19V were reported, namely B19V-induced pure amegakaryocytic thrombocytopaenia in a nine month old male infant (got cured by IVIG treatment) 20 , myositis 21 as a complication of erythema infectiosum in a nine year old female child and a series of eight cases with non-occlusive ischaemic gangrene of stomach or bowel including four cases having extensive gangrene of either entire ileum or jejunum to right colon who died post-operatively due to short gut syndrome (mortality 50%) 22 .
Further, to conduct sero-epidemiological studies, a large sample size was required and limiting factors were high cost of commercial ELISA kits and non-availability of PCR, a few decades ago. Hence, ELISA was developed in our laboratory using cloned, baculovirus expressed and purified B19V VP1 and VP2 proteins as antigens 23 . To further detect early viraemic cases, detection of B19V DNA was required; hence, in-house DNA extraction from serum and then, PCR and nested-PCR were developed and standardized 17, 23, 24 . Seroepidemiology and B19V susceptibility of general population to acquire B19V infection were determined by estimating B19V-specific IgG antibodies to B19V capsid proteins VP1 and VP2 by in-house ELISA in 1000 voluntary blood donors (patient's relatives) and it came out to be 39.9 per cent 23 similar to a study from Japan 25 . This indicates that about 60 per cent of Indian population (now about 1.25 billion) is non-immune. Seroprevalence of B19V in different age-groups in our country has been reported in 5 per cent children less than 10 yr, in 13 per cent young adults of 10-20 yr and in 44 per cent of aged 20-60 years 26 . These data show that a major proportion of population, especially children and young adults, are susceptible and prone to acquire to B19V infection.
A study on foeto-pathogenic association of B19V was then done on 372 women, and B19V infection was found in 19.8 per cent of 116 women with recurrent spontaneous abortions, 11 per cent among 136 pregnant women and 5 per cent among 120 non-pregnant women 27 . In another study, 60 high-risk pregnant women with bad obstetric history and having polyhydramnios, oligohydramnios or intrauterine growth retardation were examined and B19V infection was found in 13.6 per cent 28 . In a study on 35 cases of paediatric haematological malignancies, B19V infection was seen in 17.1 per cent [5 acute lymphoblastic leukaemia (ALL), 1 Non-Hodgkin's lymphoma (NHL)] children while two children also had B19V DNA in serum besides giant pronormoblasts (lantern cells) 29 in the bone marrow. Another study on 90 children with beta-thalassaemia major who were multi-transfused had high B19V seropositivity in 81 per cent and high anti-B19V IgM positivity of 41 per cent besides transmission occurred through B19V-infected donor units 30 .
Novel clinical manifestations of B19V by PCR were further analyzed by real-time PCR 31 which comprised amegakaryocytic thrombocytopenia, non-occlusive ischaemic gangrene of stomach and bowel and on B19V-induced myositis which has been reported further 32, 33 . Another finding was of a novel 'oncolytic property' in children with leukaemia mostly ALL based on mortality of 17.1 per cent among B19V-uninfected groupin comparison to none (0%) in B19V-infected group besides finding unexplained prolonged remission in a child with chronic myeloid leukaemia which supported our hypothesis that B19V might have an oncolytic property 34, 35 . Some of the articles published by our group are summarized in Table I. Other investigators also began to report cases of B19V infection from India and B19V infections were reported in 20 per cent (n=50) in patients with haematologic disorders with aggravation of anaemia 37, 38 . Others found B19V genotypes 1 and 3 in patients with solid and haematological cancers 39, 40 , and B19V infection in a prolonged anaemia in a case with dilated cardiomyopathy (DCM) 41 .
Multiorgan afflictions by human parvovirus B19 (B19V) and its pathogenic mechanisms
From four types of clinical infection recognized earlier beginning with TAC, erythema infectiosum, arthropathy and non-immune hydrops foetalis now multiorgan afflictions by B19V (Table II) and its pathogenic features are being elaborated beginning with heart (vide infra).
Cardiovascular affliction
Numerous reports point B19V as a new cardiotropic virus that may frequently cause acute inflammatory myocarditis (iMC) which leads to DCM 42, 43 and isolated ventricular diastolic dysfunction 44 . B19V has been reported to infect intracardiac endothelial cells of arterioles or venules which may impair microcirculation of the myocardial cells besides owing to inflammatory cells penetration into the myocardium and may cause 42, 43 . Further, genotypes 1 and 2 of B19V have been commonly detected in endomyocardial tissues of myocarditis (MC), while genotype 2 is more common in iMC and in females 45 . Active B19V infection in such patients was documented by the finding of B19V-mRNA replication intermediates; study at molecular level showed B19V reactivation from latency and induction of altered cardiac gene expression in a subgroup of cardiomyopathy patients 45, 46 . Endothelial cell regeneration may also be inhibited through B19V-infected circulating angiogenic cells in patients with DCM 47 . B19V association in the pathogenesis of MC and its progression towards MC/ DCM remains unproven. 
Renal affliction
Renal afflictions of B19V have been reported in a variety of clinical situations with pathological lesions 73 such as acute thrombotic microangiopathy 48 , focal segmental glomerulosclerosis or collapsing glomerulopathy 49, 50 , post-infectious glomerulonephritis 51 , endocapillary proliferative glomerulonephritis 52 and anaemia in renal transplant recipients 53 . Mechanisms involved in these renal pathologies, which are associated with B19V may include causation of vasculitic changes in intra-renal small-and medium-sized blood vessels, production of cytopathic effects on glomerular epithelial or endothelial cells and massive deposition of immune complexes on subendothelial cells which is seen as electron-dense deposits on electron microscopy and all these pathological lesions result clinically in impaired immune responses, deficient production of erythropoietin besides decrease in erythrocyte survival 47, 51, 52 . It has been estimated that only two per cent renal transplant recipients get B19V infection while another study reports it as high as 30 per cent 52, 53 .
Hepatic affliction
Liver infection by B19V has been reported as a possible causative agent of hepatitis or hepatitis with anaemia and even acute liver failure based on finding of B19V DNA in liver tissue in children with fulminant liver failure and aplastic anaemia [54] [55] [56] [57] 74 . We also found B19V as a sole causative agent in a few children with acute viral hepatitis, but most children had B19V co-infection along with other hepatotropic viruses 18 . Currently, B19V-induced hepatitis is under-recognized though it may cause elevation of liver transaminases, acute or chronic hepatitis and rarely fulminant liver failure, and it can also cause macrophage activation syndrome that may be fatal and fibrosing cholestatic hepatitis 75 . Although foetal hepatocytes have receptors for B19V, later in adults, it is non-permissive infection and it may be serious enough to require liver transplantation or bone marrow failure 76 ; the mechanism of B19V-induced hepatic injury is unclear, but experiment in mice has shown direct hepatic injury through non-structural-1 protein (NS1) or VP1 unique region (VP1u) proteins of B19V 77, 78 .
Neurological affliction
A systematic review on neurological involvement of B19V-related infections included 129 patients, of whom 79 (61.2%) had central nervous system manifestations, 41 (31.8%) had peripheral nervous system manifestations and nine (7%) had myalgic encephalomyelitis, but most had encephalitis (50/129) ultimately 79 . Several other neurological afflictions 80, 81 , acute encephalitis and encephalopathy 58 , focal seizure 59, 60 , acute cerebellitis 61 , mononeuropathy multiplex 62 , and Guillain-Barré syndrome 63 have been reported, but the mechanism is largely obscure; however, molecular mimicry and autoimmunity to basic myelin protein are most likely as in multiple sclerosis 64 .
Placental infection by B19V besides causing well-documented non-immune hydrops foetalis, has also been reported to cause foetal anaemia and spontaneous abortions 82 , congenital infections 83 and more serious placental abruptions 84 . Gut infections due to B19V infection has been shown to be localized in the intestinal mucosa andreported to cause severe inflammatory bowel disease 85, 86 while non-occlusive ischaemic gangrene of stomach or bowel caused by B19V was reported by us 22 . Recently, splenic infarct due to B19V has been reported 87 .
Haematological affliction
Haematological 88 infections due to B19V presenting as aplastic crisis 2 were the first documented clinical manifestation of this virus. B19V targets erythroid progenitor cells such as erythroblast in the bone marrow and may causes lytic infection resulting in severe anemia 11, 65 , PRCA which may lead to myelodysplasia 17 . Non-erythroid cell 68 infections by B19V involving platelets are uncommon but may occur as some of the thrombocytes are known to possess receptor for B19V and thus cause thrombocytopaenia with anaemia or bicytopaenias 18, 19 , while our report on acquired pure amegakaryocytic thrombocytopenia 20 remains solitary. Other afflictions such as macrophage activation as in haemophagocytosis syndrome 19 induced by B19V are also rare. Further, non-erythroid cell 68 69 while more severe disorders reported are pancytopenia 70 , bone marrow failures 71 , aplastic anaemia and necrosis of bone marrow or fat embolism 89 .
infections of leucocytic cells by B19V include leucopenia and agranulocytosis
In leukaemia especially in children with ALL, B19V infection may precede or precipitate leukaemia and may also complicate the course of leukaemia by causing persistent anaemia and requiring prolonged duration of induction therapy 29, 90, 91 . B19V has been proposed to cause leukaemia through methylation of cancer genes by anti-B19V IgG and deficient production of IL-10 at birth 72 . B19V may have a dual role, one in causation of leukaemia and second possession of natural oncolytic property of B19V 34, 35 or controlling leukaemia and preventing deaths in children with ALL.
Cutaneous affliction
Cutaneous manifestations of B19V are uncommon and varied from rash of erythema infectiosum to purpuric-petechial eruption, pseudo-erysipelas 92, 93 and scleroderma 94 . Mechanism is mostly due to immune complex mediated, but B19V may directly infect endothelial cells as well as fibroblasts in the skin with enhanced tumour necrosis factor (TNF)-alpha expression and vascular deposition of C5b-9 in the endothelial cells besides neoantigenicityand cell injury as seen in scleroderma 94 . Recently, we reported a four year old child with drug rash and eosinophilia with systemic symptoms syndrome on fluoxetine and complicated by B19V infection 36 .
Organ transplantation & other organs
Surgeons transplanting heart, liver or kidney may face problems due to B19V infection mostly as PRCA 95, 96 , and it may cause severe organ failure requiring transplantations 75 . Transfusion of blood or blood products from a viraemic donor can transmit B19V infection since B19V causes high titre viraemia 97 . Moreover, dual viral inactivation method have also failed to eliminate B19V from blood products which are cause of concern 97,98 .
Other organs which may be infected by B19V are epithelioid cell granuloma of the lungs 99,100 while infections of the eyes includeuveitis 101, 102 , retinal pigment epitheliopathy, retinal detachment and ophthalmoparesis [103] [104] [105] . B19V may infect internal ears and produce hearing loss and dizziness which are probably immune mediated 106, 107 . In testicular tissues, B19V DNA has been detected in patients with germ cell tumour 108, 109 .
Pathogenicity and virus host-cell interactions
B19V is known to have tropism for human erythroid progenitors 17 due to the presence of a globoside (Gb4Cer) receptor for B19V 110, 111 which is also present in non-erythroid tissues such as endothelial cells and foetal hepatocytes, placental trophoblastic cells and some megakaryocytes cells 68 . Two co-receptors of B19V, namely α5β1 integrin 112 , a fibronectin and another Ku80 autoantigen 113 help in exteriorisation of B19V.
Toxic effects are exerted by several B19V viral proteins on various types of human cells. For instance, B19V infects bone marrow and multiplies causing interference in erythropoiesis (about 55% inhibition) due to lytic or direct cytopathic effect which is mediated by VP2 protein of B19V. B19V inhibits colony forming unit-erythroid (cfu-E) and blast forming unit-erythroid (bfu-E) colonies of erythroid series cells in the bone marrow resulting in sudden drop of haemoglobin 66, 67 . Further interaction with Fas ligand 114 through interferon-gamma induces apoptosis by caspase activation and this culminates in severe anaemia, PRCA, myelodysplasia 17 , thrombocytopaenia 18 sometimes neutropaenia and pancytopaenia 111, 115 .
Persistent infection by B19V in erythroid cells as well as in the non-erythroid 68 lineage cells and other body tissues such as myocardial endothelial cells is another important virulence mechanism of B19V in the causation of multi-tissue and multiorgan diseases. Low-level expression of viral gene has been observed in some cells with persistent infection and B19V capsid mRNA or proteins have been detected in the bone marrow, synovial, heart, liver, colon, lymphoid, thyroid and testicular tissues with different disease outcomes 116, 117 . Since vascular endothelial cells line all blood vessels which in turn supply blood to all organs through arteries, arterioles and capillaries and possess receptor for B19V, these get infected by B19V and induce multi-systemic vasculitis, necrotizing vasculitis, endothelialitis and micro-angiopathy [118] [119] [120] and cause various diseases. To study the mechanisms underlying B19V infection and B19V DNA replication, many types of cell culture systems, including permissive and semipermissive erythroid lineage cells besides non-permissive cells, such as human embryonic kidney 293 or the endothelial cells of the myocardium, have been utilized 121 . B19V uptake into endothelial cells may get facilitated due to antibody-mediated enhancement through complement factor C1q 122 .
Molecular mechanisms of pathogenicity include
VP1u and NS1 proteins of B19V which cause cellular cytotoxicity and apoptosis by caspase 3 and 9 pathways or immune-mediated molecular mimicry with several known human auto antigens such as collagen II, cardiolipin, keratin, myelin basic protein and platelet membrane glycoprotein IIb and IIIa, which are presented as self-antigens to T-lymphocytes; further, B19V VP1u protein with phospholipase activity may cleave host DNA 116, 117 . In addition, inflammatory signalling may be modulated through B19V NS1 protein due to activation of STAT3/PIAS3 in human endothelial cells 123 .
New insights in pathogenicity and evidence
Multiorgan infection by B19V has been reported in an allogenic stem cell transplant recipient patient 124 . Globoside (Gb4Cer) is the main receptor of B19V 110, 125 which is present on the membrane of erythroid progenitor cells that bind to VP2 protein of B19V 47 and felicitate its internalization 126 . Therefore, B19V was regarded to possess "narrow tissue tropism" being known to infect and propagate only in erythroid progenitor cells in the "bone marrow" which is the major site of B19V replication and persistence 127, 128 besides restricted persistence in the synovium in cases of arthritis 129 and henceforth thought to cause 'haematological disorders' 97 only. In contrast to this previous belief, there is need to change the view now since B19V can also infect and persist in different kinds of non-erythroid cells and even in placental trophoblast cells 130 .
Possession of multiple receptors by human parvovirus B19
Multi-tissue and multiorgan infection by B19V is due to broad expression and pattern of Gb4Cer receptor that binds to B19V; however, in addition, B19V possess α5β1 integrin 112 and Ku80 autoantigen 113 as co-receptors. Ku80 auto-antigen is host nuclear protein and is present on several host cells such as immune cells, erythroblasts, B-cells, T-cells, macrophages in bone marrow, tonsils and follicular dendritic cells in the joints 113 . Other receptors of B19V include multiple glycosphingolipids (GSLs) 131 which determine the tissue tropism of B19V. Thus, B19V possesses multiple receptors, distributed in multiple tissue types widely both on erythroid 110 , non-erythroid 111 , myeloblasts 132 and more importantly vascular endothelial cells.
B19V DNA has been detected in intracardiac vascular endothelial cells within the myocardium in cases of inflammatory cardiomyopathies as also in kidneys causing endothelialitis and other vasculitic injuiries 119 ; further, thrombotic microangiopathy 121 and placental endothelial cells infection may occur 133 . Mechanism of B19V endothelial damage may also be through circulating immune complexes or more importantly by direct invasion of the vascular endothelium by B19V 121 . Parasitism of endothelial cells and fibroblasts by B19V can cause endothelial neoantigenicity and enhanced TNF-alpha expression and this mechanism has been reported in scleroderma 94 .
The pathogenic effects have been associated with B19V VP1u protein which becomes accessible after attachment to the globoside receptor and can bind to other cells 134, 135 . It is possible for B19V to have other unexplored co-receptors. Other factors may include micro-environment such as the presence of hypoxia 136 which may enhance B19V productive infection as shown in cultured erythroid progenitor cells.
Evidences from animal parvovirus infections
Organ involvement by B19V has also been reported in animals by animal parvoviruses such as infection by canine parvovirus type-2 which has been reported to cause massive necrotizing MC in a mongrel puppy 137 or enteritis causing death of a wild wolf 138 . A study in cats and dogs infected with animal parvoviruses showed intestinal lesions characteristic of feline or canine parvovirus infection with the detection of parvoviral DNA and antigen in the intestines 139 .
Time to realize the threat and attempts towards prevention
Organs or tissue detection of B19V DNA is often missed owing to cryptic 140 sites of infection or due to unknown tissue distribution of B19V or being in low copies numbers of virions. Similar is the case of anti-B19V IgM antibodies which may not be detected in many of immunocompromised patients infected with B19V owing to failure in mounting of antibodies in sufficient quantities andtitresremain low. These leads to false-negative results owing to which a good proportion of actually B19V infected cases go undiagnosed causing underestimation of clinical impact of B19V infection in the population globally. Now almost 40 years since its discovery disease burden due to B19V infection and associated mortality has not been determined largely because of lack of large series studies and vast majority being case reports. There is a need to recognize B19V infection as a sinister virus and for its prevention, there are no specific antiviral agents available in the present time. Recombinant B19V vaccine was developed in early nineties comprising VP1 with VP2 proteins and found immunogenic in animal 141 . Later double-blind, randomized, phase 1 clinical trial on B19V seronegative adults showed the vaccine as safe as well as immunogenic 142 . A phase II clinical trial which was underway has been terminated (https://clinicaltrials.gov/ct2/show/NCT00379938), under the belief that it may not be commercially feasible. There are issues on toxigenicity which remain to be solved, and meanwhile, drugs like cidofovir are being tested 143 .
Due to lack of efficient adaptation to cellular cultures and absence of animal models, the Koch's postulate remains unproven in the causation of a wide spectrum of clinical diseases due to parvovirus B19V 10 ; however, with advances in molecular techniques and direct demonstration of viral genomes in infected tissues, an alternative method proposed is 'molecular Koch's postulates' 144 . The research in B19V infections should be continued and B19V should gain its full recognition as an important pathogenic virus of public health importance globally 145 .
Conclusion
Nearly half of adult population of the world irrespective of age, sex and geographic location has been found to be B19V seronegative hence is prone to acquire B19V infection. Earlier, B19V was known to exert great tropism for erythroid progenitors in the bone marrow as these possess Gb4Cer receptors and thought to be restricted in causing haematological diseases only. Now, owing to recent recognition of multiple GSL receptors and co-receptors of B19V which are distributed widely on host tissues, explains multi-tissue or multiorgan diseases that may be caused by B19V. B19V has been reported to infect non-erythroid cells as well as vascular endothelial cells and produces a wide spectrum of clinical infections. Cellular pathogenicity is further substantiated by B19V causing endothelialitis, vasculitic and complement-mediated injuries. B19V-specific proteins especially NS1,VP2 and VP1u, molecular mimicry and immune enhancement besides potential to cause persistent infection points more to words a causal role of B19V in multiorgan diseases rather than a casual detection.
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